EMEric Monsalves

Eric Monsalves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Monsalves has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics

    by James A. Balogun, Eric Monsalves, Kyle Juraschka, Kashif Parvez, Walter Kucharczyk, Ozgur Mete, Fred Gentili, Gelareh Zadeh

    The aim of the study was to establish if the null cell adenoma (NCA) forms a distinct subgroup with unique clinicopathological characteristics within the nonfunctioning pituitary adenoma group particularly in relation to the silent gonadotroph adenomas (SGAs). We identified 31 patients with the pathological diagnosis of NCA verified by routine histology and immunohistochemistry with distinct differentiation from SGAs by an established negative testing for SF-1 at the Toronto Western Hospital between December 2004 and August 2010. We reviewed their demographic data, clinical features, magnetic resonance imaging, and the histologic variables: MIB-1, FGFR4, and P27. We compared these to 63 SGAs identified within the same period. All the NCAs were macroadenomas with diameter ranging from 15—57 mm and tumor volumes between 1.95–53.5 mm3. Preoperative cavernous sinus tumor growth was able to predict the presence of a residual after surgery (p = 0.023). Furthermore, preoperative cavernous sinus extension (p = 0.002) and negative P27 expression (p = 0.035) were able to independently predict the subsequent growth of the postoperative tumor residual. Comparing the NCA to SGA, we found that MIB-1 was higher in NCA (mean ± SD = 3.43 ± 2.76 %) compared to SGAs (mean ± SD = 2.49 ± 1.41 %) (p = 0.044). The preoperative and postoperative tumor volume doubling times (TVDTs) displayed a negative correlation in the SGA (r = −0.855, p = 0.002) while in the NCA, a positive correlation was evident (r = 0.718, p = 0.029). Our study suggests that the NCAs are a distinct group with differing behavioral characteristics from the SGAs. It also appears that the finding of cavernous sinus extension on preoperative imaging and a negative P27 expression on immunohistochemistry in NCAs may be valuable tools in predicting residual tumor growth which may impact on postoperative care.


  • Does Natural History of Vestibular Schwannomas Govern Treatment Response and Complications to Radiosurgery?

    by Soroush Larjani, Hooman Pebdani, Eric Monsalves, Caroline Hayhurst, Boris Krischek, Fred Gentili, Michael Cusimano, Normand Laperriere, Gelareh Zadeh

    Purpose: To determine whether the natural history of vestibular schwannomas (VSs) predict tumor response to radiosurgery and incidence of new adverse radiation effects (ARE). Methods and Materials: A retrospective review of a prospectively maintained database of all VS patients treated with a 12-Gy prescription dose between September 2005 and June 2011 at our institution using the Leksell Model 4C Gamma Knife Unit (Elekta Instrument, Atlanta, GA) was conducted. Of the 258 patients treated, 63 had clinical and radiological follow-up at least 12 months before and after radiosurgery and were therefore included in this study. Tumor growth rate before and after radiosurgery were calculated using the specific growth rate (SGR). Tumor volumes were measured based on FIESTA MRI scans obtained at 6-month intervals (pre- and post-radiosurgery) using ITK-SNAP v2.2. All radiation parameters and ARE were collected. All analyses were performed with IBM SPSS v20.0. Results: Following radiosurgery, 27 (42.9%) patients showed a significant decrease in volume after 1 year, 29 (46.0%) stabilized, and 7 (11.1%) continued to grow. There was no correlation between pretreatment and post-treatment VS growth rates (P = 0.34). However, the extent of decline in tumor growth rates after radiosurgery was directly proportional to pretreatment growth rates. None of the pretreatment predictive factors investigated, such as treatment volume, age on date of treatment, patients’ gender, radiation, and dosimetry parameters had any significant relation with pre- or post-treatment tumor growth rates. Univariate analysis of risk factors revealed a significant positive correlation between post-treatment tumor growth rates and incidence of ARE (P = 0.047). Conclusions: Pretreatment growth rates of VSs do not predict tumor response to radiosurgery or incidence of ARE. A higher pretreatment growth rate was predictive of the decline in growth rate after treatment. Patients who experienced ARE were more likely to have VSs that continued to grow after radiosurgery.

  • Endoscopic Endonasal Transsphenoidal Approach to Large and Giant Pituitary Adenomas: Institutional Experience and Predictors of Extent of Resection

    by Kyle Juraschka, Boris Krischek, Eric Monsalves, Alex Kilian, Aisha Ghare, Bruno L. Godoy, Alan Vescan, Fred Gentili, Gelareh Zadeh

    Objective: While the use of endoscopic approaches has become increasingly accepted in the resection of pituitary adenomas, limited evidence exists regarding the success of this technique for patients with large and giant pituitary adenomas. This study presents the outcomes of a large cohort of patients with large and giant pituitary adenomas who underwent endoscopic endonasal transsphenoidal surgery (EETS) at our institution. It focuses on identifying factors that can predict extent of resection, and hence aid in developing guidelines and indications for the use of EETS versus open craniotomy approaches to large and giant pituitary adenomas. Methods: We reviewed 487 patients who underwent EETS resection of sellar masses. From this group, 73 consecutive patients with large and giant pituitary adenomas (defined as maximum diameter ≥ 3 cm and tumor volume ≥ 10 cm3) who underwent EETS between January 2006 and May 2012 were included in the study. Clinical presentation, radiographic studies, laboratory investigations, tumor pathology data, clinical outcomes, extent of resection measured by volumetric analysis, and complications were analyzed. Results: Mean preoperative tumor diameter in this series was 4.1 cm and volume was 18.43 cm3. The average resection rate was 82.9%, corresponding with a mean residual volume of 3.15 cm3. Gross total resection was achieved for 16 patients (24.2%), near total in 11 (16.7%), subtotal in 24 (36.4%), and partial in 15 (22.7%). In 73.0% of patients, visual acuity improved, and 23.8% were unchanged. Visual fields were improved in 61.8% and unchanged in 38.2%. Overall, 27 patients (37.0%) experienced a total of 32 complications. The most common complications were sinusitis (13.7%) and CSF leak (9.6%). Six patients underwent subsequent radiation therapy due to aggressive tumor histopathology. No deaths occurred in this cohort of patients. Statistically significant predictors of extent of resection included highest Knosp Grade (P = 0.000), preoperative tumor volume (P = 0.025), preoperative maximum tumor diameter (P = 0.002), hemorrhagic component (P = 0.049), posterior extension (P = 0.000), and sphenoid sinus invasion (P = 0.005). Anterior extension, lateral extension beyond the carotids in the intracranial component, optic nerve compression, cystic components, cell type, and tumor markers were not statistically significant predictors of extent of resection. Conclusions: EETS is an effective treatment method for patients with giant pituitary adenomas, which results in high (>80%) rates of resection and improvement in visual function. It is not associated with high rates of major complications and is safe when performed by experienced surgeons. The preoperative Knosp Grade, tumor volume, tumor diameter, hemorrhagic components on MRI, posterior extension, and sphenoid sinus invasion may allow prediction of extent of resection.


  • Patterns of Tumor Response and Nonauditory Morbidity Following Contemporary Reduced Dose Gamma Knife Radiosurgery for Vestibular Schwannoma

    by Gelareh Zadeh, Eric Monsalves, Caroline Hayhurst

    Background: The concept of initial increase in tumor size after radiosurgery (pseudoprogression) is increasingly recognized. We aim to define patterns of tumor response with a 12-Gy marginal dose and assess the impact of dosimetry characteristics on tumor control and complications. Methods: Two hundred patients were treated between September 2005 and December 2009, and 80 had complete follow-up for at least 24 months (mean 31 months). Tumor response is classified as stable, initial increase then stable, and growth requiring intervention. All treatment plans were reviewed for 12-Gy volume, conformance index, brainstem, and trigeminal nerve dose. Results: Sixty patients (75%) had stable tumors; 16 (20%) showed initial increase in size, which then stabilized; 4 (5%) required salvage; 27 (33.8%) developed complications; 5 (6%) developed hydrocephalus; 10 (12.5%) developed ataxia; 17 (21%) had trigeminal dysfunction; 4 (5%) had facial weakness; and 1 patient developed hemifacial spasm. Tumor volume and brainstem radiation dose were significant predictors of complications (P ≤ 0.001). The presence of edema was significantly associated with complications (P = 0.004). Tumor response (stable or pseudoprogression) was not predictive of morbidity (P = 0.23). Conclusions: Initial treatment volume is the most important predictor of adverse radiation effects. Although pseudoprogression is common, it does not appear to be independently linked to post-treatment morbidity.

  • Open Access

    Radiation Therapy

    by Arnab Charkravarti, Meihua Wang, Ian Robins, Abhijit Guha, Walter Curren, David Brachman, Christopher Schultz, Ali Choucair, Marisa Dolled-Filhart, Jason Christiansen, et al.

    CONTEXT: Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated with mediating treatment resistance in glioblastoma multiformes (GBMs). OBJECTIVES: To identify a subset of GBM patients who may benefit from the addition of gefitinib to radiation therapy (RT) through molecular profiling. Using preclinical models, to identify strategies to overcome putative resistance to both RT alone and RT + gefitinib identified from the correlative clinical study. DESIGN: RTOG 0211 was a phase I/II study with 31 patients enrolled for phase I and 147 patients for phase II. Tissue microarrays (70 cases from RTOG 0211, 112 from historical controls) were used for clinical molecular correlative analysis. RESULTS: There was no median overall survival benefit for patients treated with gefitinib + RT versus RT alone. Younger age was significantly associated with better outcome (HR ≥ 50 vs. P = 0.0037) in RTOG 0211-treated patients. After adjusting for age, higher levels of SRC and IGFR1 were associated with adverse overall survival in RTOG 0211-treated patients. A cautionary note, GBM patients with elevated levels of SRC and PTEN appeared to have significantly improved overall survival if treated by RT alone versus RT + gefitinib. Patients with lower levels of PTEN appeared to trend towards improved clinical outcome when treated with RT + gefitinib versus RT alone. Addition of SRC inhibitors in the context of high SRC expression or overexpression of PTEN in the context of low PTEN expression could restore the therapeutic benefit of gefitinib in preclinical models. CONCLUSIONS: The addition of gefitinib to RT does not appear to benefit the general, unselected population of GBM patients. Of cautionary significance, our findings reveal biomarker profiles that predict worse outcomes in the setting of combined gefitinib + RT versus RT alone.